



## Pregnancy-associated plasma protein-A (PAPP-A)



**P**regnancy-associated plasma protein-A (PAPP-A) is a metalloprotease that belongs to the metzincin superfamily of zinc peptidases. Its main substrate is insulin-like growth factor binding protein (IGFBP) 4. This cleavage causes release of bound IGF, which plays an important role in promoting cell

differentiation and proliferation. PAPP-A was first identified from the serum of pregnant women, hence its name. Later, it was shown to be expressed in multiple tissues.

### Two forms of PAPP-A

*Heterotetrameric PAPP-A* (htPAPP-A) is a screening marker for Down syndrome. htPAPP-A level in maternal serum increases with gestational age until term. If the concentration of htPAPP-A in the first trimester is markedly decreased, this indicates a higher risk of Down syndrome (1).

htPAPP-A is a protein complex consisting of two PAPP-A subunits and two proforms of eosinophil basic proteins (proMBP) covalently linked to each other. proMBP has been shown to inhibit the protease activity of PAPP-A in this heteromeric complex (2).

*Homodimeric PAPP-A* (dPAPP-A) is abundantly expressed in unstable coronary atherosclerotic plaques (3). dPAPP-A circulates as a homodimer and not in complex with proMBP. Based on several studies dPAPP-A has been considered to be a promising marker of plaque destabilization in patients with acute coronary syndrome (ACS). Unfortunately, dPAPP-A assays have been shown to also detect htPAPP-A, the Down syndrome marker not related to atherosclerotic plaques. In order to prevent this, a dPAPP-A assay should be designed so that it only recognizes dPAPP-A and does not cross-react with htPAPP-A.

Another limitation to the use of dPAPP-A as a cardiac marker is the fact that the measurements were shown to be affected by heparin, an anti-coagulation agent often used as part of the treatment procedure with patients suffering from acute myocardial infarction. So in order to use dPAPP-A as a cardiac biomarker the heparin injections should be taken into account when analyzing the samples.

A promising surrogate marker for dPAPP-A is its main substrate IGFBP-4. For more information, please see our IGFBP-4 TechNotes.

### Reagents for immunoassay development

We provide monoclonal antibodies (MAbs) specific to PAPP-A and proMBP that allow for the development of highly sensitive, quantitative htPAPP-A immunoassays. We also provide a selection of MAbs that only detect dPAPP-A and do not cross-react with htPAPP-A.

In addition, we provide htPAPP-A antigen purified from retroplacental blood. HyTest is the largest global supplier of this product.



### CLINICAL UTILITY

- ✓ First trimester screening marker for Down syndrome
- ✓ Marker of atherosclerotic plaque destabilization

### Monoclonal antibodies specific to htPAPP-A


We provide several different MAbs specific to htPAPP-A. Some of the MAbs recognize the PAPP-A subunit while some are specific to the proMBP part of the heterotetrameric complex.

### Total PAPP-A and htPAPP-A sandwich immunoassays

All MAbs were tested in pairs in sandwich fluoroimmunoassays as capture and detection antibodies with both forms of the antigen - htPAPP-A and dPAPP-A. The antibody pairs performing best in our in-house assays are listed in Table 1. Calibration curves for two suggested pairs are shown in Figure 1.

**Table 1. Recommended pairs for htPAPP-A and total PAPP-A sandwich immunoassay.**

| Detection of human htPAPP-A antigen (capture - detection) | Detection of total PAPP-A (htPAPP-A and/or dPAPP-A) (capture - detection) |
|---|---|
| 10E2 - 5H9  | 10E2 - 10E1   |
| 5H9 - 10E2  | 4G11 - 3C8  |
| 5H9 - 7A6   | 4G11 - 10H9   |
| 10E1 - 11E4   | 10E1 - 7A6  |




**Figure 1. Calibration curves for two PAPP-A sandwich immunoassays. (A) 4G11 - 3C8 and (B) 4G11 - 10H9.**

Capture MAb: 4G11 (biotinylated)  
 Detection MAbs: 3C8 or 10H9 (labeled with stable Eu<sup>3+</sup>-chelate)  
 Antigen: htPAPP-A  
 Mixture of antibodies and antigen was incubated for 30 minutes at room temperature in streptavidin-coated plates.

### PAPP-A immunodetection in Western blotting

MAbs 3C8 and 7A6 recognize PAPP-A subunit whereas MAbs 5H9 and 11E4 recognize the proMBP subunit of htPAPP-A in Western blotting after SDS-PAGE in reducing and non-reducing conditions. MAbs 4G11 and 10E1 recognize htPAPP-A in Western blotting only after electrophoresis in nonreducing conditions (see Figure 2 and data not shown here).



**Figure 2. Detection of human PAPP-A and proMBP subunits of htPAPP-A by monoclonal antibodies in Western blotting.**

Lane 1: 7A6  
 Lane 2: 3C8  
 Lane 3: 5H9 (proMBP-specific)  
 Lane 4: 11E4 (proMBP-specific)  
 Lane 5: 7A6  
 Lane 6: 3C8  
 Lane 7: 10E1  
**Lanes 1-4:** after SDS-PAGE in reduction conditions.  
**Lanes 5-7:** Non-reducing conditions. Heterotetrameric complex was detected by anti-PAPP-A MAbs.

**Monoclonal antibodies specific to dPAPP-A**

We offer a few MABs that only recognize dPAPP-A and do not cross-react with htPAPP-A.


**Selective dPAPP-A sandwich immunoassay**

We recommend two MAB combinations for the development of dPAPP-A sandwich immunoassay (Table 2). In these prototype assays one of the MABs is specific to dPAPP-A (Cat.# 4PD4), while the other MAB can recognize all known forms of PAPP-A (Cat.# 4P41). The recommended combinations were tested with dPAPP-A purified from atherosclerotic coronary arteries, as well as with purified htPAPP-A (Cat.# 8P64) and human recombinant dPAPP-A (in-house preparation). The prototype assays were able to recognize dimeric forms of the antigen with high specificity and with negligible cross-reactivity (< 1%) with htPAPP-A. These MAB combinations could be used for the development of highly sensitive sandwich immunoassays that are suitable for the selective quantitative measurements of dPAPP-A in human blood.

**Table 2. Recommended pairs for dPAPP-A sandwich immunoassay.**

| Capture | Detection |
|---------|-----------|
| PAPP52  | PAPP30    |
| PAPP2   | 7A6       |

Figure 3 shows the calibration curves for the PAPP2-7A6 sandwich fluoroimmunoassay. The detection limit of the immunoassay was better than 0.3 ng/ml with human recombinant dPAPP-A (in-house preparation) used as a calibrator. This assay revealed very low (< 1%) cross-reactivity with the heterotetrameric form of PAPP-A.




**Figure 3. Calibration curves for a dPAPP-A immunoassay.**

Capture MAb: PAPP2  
 Detection MAb: 7A6 (labeled by Eu<sup>3+</sup> chelate)  
 Incubation volume 100 µl.  
 Incubation time: 30 min at room temperature.

**dPAPP-A levels in the blood of patients with ACS**

We measured the concentration of dPAPP-A in the plasma from 43 patients with ACS (acute myocardial infarction, unstable angina) using the prototype assay PAPP52-PAPP30. The samples were withdrawn 3-20 hours following the onset of chest pain. As a control, we used plasma samples obtained from 34 non-ACS patients. The dPAPP-A levels in plasma from ACS patients were 2.77 fold higher than in plasma from the control group (P<0.0005) (see Figure 4).



**Figure 4. dPAPP-A concentration in plasma samples of 43 ACS patients (ACS) and 34 non-ACS patients control group (Normal) measured by PAPP52 - PAPP30 sandwich immunoassay (mean±SD).**

Capture MAb: PAPP52  
 Detection MAb: PAPP30 (labeled with Eu<sup>3+</sup> chelate)  
 Incubation volume: 100 µl.  
 Incubation time: 30 min at room temperature.

### Heterotetrameric PAPP-A/proMBP complex (htPAPP-A)

HyTest's htPAPP-A is purified from the pooled retroplacental blood and purity is over 85% according to SDS-PAGE (Figure 5). htPAPP-A is recognized by monoclonal antibodies specific to different parts of PAPP-A or proMBP (Cat # 4P41). Antigen can be used as a calibrator for total PAPP-A and htPAPP-A sandwich immunoassays.

**Figure 5. SDS-gel electrophoresis of htPAPP-A in reducing conditions.**


Lane 1: molecular weight standards

Lanes 2, 3: human htPAPP-A

Antigen loaded: 5 µg

Gel staining: **A:** Coomassie brilliant blue R-250, **B:** Stains all (staining of glycosylated proteins).

Comments: proMBP subunit migrates in gel as a diffuse band with molecular mass about 50-90 kDa and is not stained by Coomassie brilliant blue because of high degree of glycosylation (~40%).



### Ordering information

#### MONOCLONAL ANTIBODIES

| Product name   | Cat. # | MAb    | Subclass | Remarks                          |
|--|--------|--------|----------|----------------------------------|
| Pregnancy-associated plasma protein A (PAPP-A), human                  | 4P41   | 10E1   | IgG2b    | EIA, WB, PAPP-A subunit          |
|  |        | 10E2   | IgG2b    | EIA, PAPP-A subunit              |
|  |        | 5H9    | IgG2b    | EIA, proMBP subunit              |
|  |        | 4G11   | IgG2a    | EIA, WB, PAPP-A subunit          |
|  |        | 3C8    | IgG2a    | EIA, WB, PAPP-A subunit          |
|  |        | 10H9   | IgG2a    | EIA, PAPP-A subunit              |
|  |        | 11E4   | IgG2b    | WB, proMBP subunit               |
|  |        | 7A6    | IgG2a    | EIA, PAPP-A subunit              |
|  |        | PAPP52 | IgG1     | EIA, PAPP-A subunit              |
| Pregnancy-associated plasma protein A (PAPP-A), human, <i>in vitro</i> | 4P41cc | 10E1cc | IgG2b    | EIA, WB, PAPP-A subunit          |
|  |        | 10E2cc | IgG2b    | EIA, PAPP-A subunit              |
| Dimeric form of pregnancy-associated plasma protein A (dPAPP-A), human | 4PD4   | PAPP2  | IgG1     | EIA, dimeric form of PAPP-A only |
|  |        | PAPP30 | IgG1     | EIA, dimeric form of PAPP-A only |

#### ANTIGEN

| Product name                             | Cat. # | Purity | Source                      |
|--|--------|--------|-----------------------------|
| PAPP-A, heterotetrameric form (htPAPP-A) | 8P64   | >85%   | Pooled retroplacental blood |

### References

1. Palomaki GE, Lambert-Messerlian GM, Canick JA. A summary analysis of Down syndrome markers in the late first trimester.// *Adv Clin Chem.* 2007;43:177-210.
2. Overgaard, MT., Haaning, J., Boldt, HB., Olsen, IM., Laursen, LS., et al. Expression of recombinant human pregnancy-associated plasma protein-A and identification of the proform of eosinophil major basic protein as its physiological inhibitor.// *J Biol Chem;* 275:31128-33 (2000).
3. Bayes-Genis, A., Conover, C. A., Overgaard, M. T., Bailey, K. R., Christiansen, M., Holmes, D. R. Jr, et al. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes.// *N Engl J Med,* 345 (14), 1022-9 (2001).